Answers are grounded in this paper and cite their sources.
Retrospective review demonstrates improved outcomes in leptomeningeal metastases from breast cancer using trastuzumab-deruxtecan, suggesting therapeutic potential.
e14033 Background: Targeting Human Epidermal Growth Factor Receptor 2 (HER2) with an antibody drug conjugate such as trastuzumab-deruxtecan (T-DXd) may be beneficial in patients with leptomeningeal metastases (LM), with limited real-world data. Methods: We performed a retrospective review at the University of Texas MD Anderson Cancer Center for patients with LM and breast cancer in the past 5 years and found a total of 133 patients. We selected only cytology proven LM (33 patients) and then analyzed the patients that were treated with T-DXd after their LM diagnosis was made. Results: We analyzed 16 patients, all females. Median age of 49 years at LM diagnosis, with 50% white, and 93.8% non-Hispanic. Invasive ductal carcinoma was the histology in 68.8% of patients with 31.3% of invasive lobular carcinoma. All patients had brain metastases. Estrogen receptor (ER) was positive in 75% of patients, progesterone receptor (PR) was positive in 56.3%, HER2 was positive in 31.3%, and HER2 was low in 68.8%. Prior to receiving T-DXd 37.5% had received chemotherapy, and 25% had received endocrine therapy. LM directed therapy included whole brain radiation (43.8%), local radiation (37.5%), proton craniospinal radiation (18.8%), and intrathecal (IT) chemotherapy (18.8%). IT chemotherapy included topotecan with trastuzumab, cytarabine with trastuzumab, and topotecan alone. Response rate at first neuroaxis MRI after starting T-DXd was 66% (10 patients, two with complete response and 8 with partial response). Six patients were still on T-DXd at the time of our analysis, and 9 patients had died. Median time on T-DXd was 6.8 months (IQR: 2.7-12.0 months). Median time to LM diagnosis was 46.5 months (IQR 24.6-124.0 months). Eleven patients survived more than 6 months after LM diagnosis, and 8 over 12 months. Conclusions: Survival after LM diagnosis is increasing with novel therapy and our findings highlight the role of T-DXd even in the setting of low HER2. Our findings provide a single center experience in using trastuzumab-deruxtecan for LM in breast cancer patients.
No takes yet. Share an insight, caveat, or question.
Stangherlin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: